{
    "nct_id": "NCT06253130",
    "official_title": "A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation, Dose-optimization, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of PARP1 Selective Inhibitor, IMP1734, as Monotherapy in Patients With Advanced Solid Tumors",
    "inclusion_criteria": "Healthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 89 Years",
    "exclusion_criteria": "* Any investigational or approved anti-cancer therapies administered within 28 days/ before the first dose of IMP1734\n* Have received prior PARP1 selective inhibitors\n* Mean resting QTcF > 470 ms or QTcF < 340 ms\n* Active or untreated central nervous system (CNS) metastases and/or carcinomatous meningitis.\n* Infections\n\n  - An active hepatitis B/C infection\n* Any known predisposition to bleeding\n* Unable to swallow oral medications OR have malabsorption syndrome or any other uncontrolled gastrointestinal condition that might impair the bioavailability",
    "miscellaneous_criteria": "Key Inclusion Criteria\n\n* Breast cancer; must have received at least one prior chemotherapy in neoadjuvant/adjuvant/metastatic setting, must have received hormonal therapy if HR+,\n* HGSOC or high grade endometrioid EOC, fallopian tube or primary peritoneal cancer; must have received at least one prior platinum-based chemotherapy for advanced disease\n* mCRPC with ongoing ADT, must have received NHA and up to 1 prior line of taxane chemotherapy\n* Age ≥ 18 years at the time of informed consent\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤1\n* Adequate organ function\n* Life expectancy ≥ 12 weeks\n* Should have evaluable disease as defined by RECIST1.1 and/or CA125 or PSA\n* Female subjects of childbearing potential and male subjects must agree to use an effective method of contraception from study entry up to 6 months after the last dose of IMP1734\n* deleterious or suspected deleterious germline or somatic mutations of select HRR genes\n* up to 1 prior line of PARP inhibitor containing treatment\n\nKey"
}